Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center
Yıl: 2023 Cilt: 53 Sayı: 4 Sayfa Aralığı: 962 - 969 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5660 İndeks Tarihi: 31-08-2023
Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center
Öz: Background/aim: Multiple sclerosis (MS) patients may be protected against cancer because of increased immune surveillance. However, aberrant T/B cell functioning in MS may increase the risk of cancer. We aimed to compare the frequency of cancer among patients with MS with an appropriate control group matched by the variables such as age, gender, tobacco smoking history, body mass index (BMI), and family history of cancer. Materials and methods: The MS patients who were registered and followed up at the MS Center in Hacettepe University Hospitals and appropriately matched with controls were included. A self-administered questionnaire with links to the online survey was delivered. Results: Overall, 1037 responses out of 2074 in MS patients and 506 responses out of 1500 control group were included. Fourteen (1.35%) of MS patients and 18 (3.6%) of the controls were diagnosed with cancer. The odds ratio of having cancer in patients with MS compared to the control group was 0.389 (95% CI = 0.161–0.940, p < 0.05). Conclusion: There was no statistically significant difference in age, gender, tobacco smoking, and BMI between the groups after propensity score matching. The odds of having cancer were lower in our MS patients compared to the controls. The autoimmune changes responsible for the pathogenesis of MS may be responsible for the decrease in cancer risk.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmunity Reviews 2012; 11 (6-7): A386-92. https://doi.org/10.1016/j.autrev.2011.11.012
- 2. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: A systematic review. Neurology 2008; 71 (2): 129-35. https://doi.org/10.1212/01.wnl.0000316802.35974.34
- 3. Roach ES. Is multiple sclerosis an autoimmune disorder? Archives of Neurology 2004; 61 (10): 1615-1616. https://doi. org/10.1001/archneur.61.10.1615
- 4. Weiner HL. Multiple sclerosis is an inflammatory T-cell- mediated autoimmune disease. Archives of Neurology 2004; 61 (10): 1613-1615. https://doi.org/10.1001/archneur.61.10.1613
- 5. O’Gorman C, Lucas R, Taylor B. Environmental risk factors for multiple sclerosis: A review with a focus on molecular mechanisms. International Journal of Molecular Sciences 2012; 13 (9): 11718-11752. https://doi.org/10.3390/ijms130911718
- 6. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nature Clinical Practice Neurology 2008; 4 (7): 384- 398. https://doi.org/10.1038/ncpneuro0832
- 7. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Regulatory T cells and human disease. Clinical and Developmental Immunology 2007; 2007: 89195. https://doi. org/10.1155/2007/89195
- 8. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009; 72 (13): 1170-1177. https://doi. org/10.1212/01.wnl.0000345366.10455.62
- 9. Hongell K, Kurki S, Sumelahti ML, Soilu-Hanninen M. Risk of cancer among Finnish multiple sclerosis patients. Multiple Sclerosis and Related Disorders 2019; 35: 221-227. https://doi. org/10.1016/j.msard.2019.08.005
- 10. Ghajarzadeh M, Mohammadi A, Sahraian MA. Risk of cancer in multiple sclerosis (MS): A systematic review and meta-analysis. Autoimmunity Reviews 2020; 19 (10): 102650. https://doi. org/10.1016/j.autrev.2020.102650
- 11. Moisset X, Perie M, Pereira B, Dumont E, Lebrun-Frenay C, et al. Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study. PLoS One 2017; 12 (11): e0188120. https:// doi.org/10.1371/journal.pone.0188120
- 12. Gaindh D, Kavak KS, Teter B, Vaughn CB, Cookfair D, et al. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. Journal of the Neurological Sciences 2016; 370: 13-17. https://doi.org/10.1016/j.jns.2016.09.005
- 13. Etemadifar M, Jahanbani-Ardakani H, Ghaffari S, Fereidan- Esfahani M, Changaei H, et al. Cancer risk among patients with multiple sclerosis: A cohort study in Isfahan, Iran. Caspian Journal of Internal Medicine 2017; 8 (3): 172-177. https://doi. org/10.22088/cjim.8.3.172
- 14. Hajiebrahimi M, Montgomery S, Burkill S, Bahmanyar S. Risk of premenopausal and postmenopausal breast cancer among multiple sclerosis patients. PLoS One 2016; 11 (10): e0165027. https://doi.org/10.1371/journal.pone.0165027
- 15. Sun LM, Lin CL, Chung CJ, Liang JA, Sung FC, et al. Increased breast cancer risk for patients with multiple sclerosis: A nationwide population-based cohort study. European Journal of Neurology 2014; 21 (2): 238-244. https://doi.org/10.1111/ ene.12267
- 16. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behavioral Research 2011; 46 (3): 399-424. https:// doi.org/10.1080/00273171.2011.568786
- 17. Ho D, Imai K, King G, Stuart EA. Matchit: Nonparametric preprocessing for parametric causal inference. Journal of Statistical Software 2011; 42 (8): 1-28. https://doi.org/10.18637/ jss.v042.i08
- 18. Nørgaard M, Veres K, Didden EM, Wormser D, Magyari M. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Multiple Sclerosis and Related Disorders 2019; 28: 81-85. https://doi.org/10.1016/j.msard.2018.12.014
- 19. Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, et al. Cancer risk in multiple sclerosis: Findings from British Columbia, Canada. Brain 2012; 135(Pt 10): 2973-2979. https://doi.org/10.1093/ brain/aws148
- 20. Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Multiple Sclerosis Journal 2008; 14 (3): 399-405. https://doi.org/10.1177/1352458507083625
- 21. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal 2015; 21 (3): 294- 304. https://doi.org/10.1177/1352458514564489
- 22. Swann JB, Smyth MJ. Immune surveillance of tumors. Journal of Clinical Investigation 2007; 117 (5): 1137-1146. https://doi. org/10.1172/JCI31405
- 23. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis and parkinson’s disease: Record linkage studies. Journal of Neurology, Neurosurgery and Psychiatry 2010; 81 (2): 215-221. https://doi.org/10.1136/jnnp.2009.175463
- 24. Grytten N, Myhr KM, Celius EG, Benjaminsen E, Kampman M, et al. Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Multiple Sclerosis Journal 2020; 26 (12): 1569-1580. https://doi. org/10.1177/1352458519877244
- 25. Hidaka A, Sawada N, Svensson T, Goto A, Yamaji T, et al. Family history of cancer and subsequent risk of cancer: A large-scale population-based prospective study in Japan. International Journal of Cancer 2020; 147 (2): 331-337. https:// doi.org/10.1002/ijc.32724
- 26. Kaplan S, Pinar G, Kaplan B, Aslantekin F, Karabulut E, et al. The prevalence of consanguineous marriages and affecting factors in Turkey: A national survey. Journal of Biosocial Science 2016; 48 (5): 616-630. https://doi.org/10.1017/s0021932016000055
- 27. Holzmann C, Bauer I, Meyer P. Co-occurrence of multiple sclerosis and cancer in a BRCA1 positive family. European Journal of Medical Genetics 2013; 56 (10): 577-579. https://doi. org/https://doi.org/10.1016/j.ejmg.2013.07.006
- 28. Gil-Bernal R, González-Caballero JL, Espinosa-Rosso R, Gómez-Gómez C. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients. Scientific Reports 2021; 11 (1): 12533. https://doi.org/10.1038/s41598-021-91912-x
- 29. Grytten N, Myhr KM, Celius EG, Benjaminsen E, Kampman MT, et al. Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study. Multiple Sclerosis and Related Disorders 2021; 55: 103209. https://doi. org/10.1016/j.msard.2021.103209
- 30. Stamatellos VP, Siafis S, Papazisis G. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the us food and drug administration adverse event reporting system database. British Journal of Clinical Pharmacology 2021; 87 (12): 4769-4779. https://doi.org/10.1111/bcp.14916
- 31. Melamed E, Lee MW. Multiple sclerosis and cancer: The ying-yang effect of disease modifying therapies. Frontiers in Immunology 2019; 10: 2954. https://doi.org/10.3389/ fimmu.2019.02954
- 32. Mons U, Gredner T, Behrens G, Stock C, Brenner H. Cancers due to smoking and high alcohol consumption. Deutsches Ärzteblatt International 2018; 115 (35-36): 571-577. https://doi. org/10.3238/arztebl.2018.0571
- 33. Gilligan C, Anderson KG, Ladd BO, Yong YM, David M. Inaccuracies in survey reporting of alcohol consumption. BMC Public Health 2019; 19 (1): 1639. https://doi.org/10.1186/ s12889-019-7987-3
- 34. Livingston M, Callinan S. Underreporting in alcohol surveys: Whose drinking is underestimated? Journal of Studies on Alcohol and Drugs 2015; 76 (1): 158-164.
- 35. Suominen S, Koskenvuo K, Sillanmäki L, Vahtera J, Korkeila K, et al. Non-response in a nationwide follow-up postal survey in Finland: A register-based mortality analysis of respondents and non-respondents of the health and social support (HESSUP) study. BMJ Open 2012; 2 (2): e000657. https://doi.org/10.1136/ bmjopen-2011-000657
- 36. Greene N, Greenland S, Olsen J, Nohr EA. Estimating bias from loss to follow-up in the Danish national birth cohort. Epidemiology 2011; 22 (6): 815-822. https://doi.org/10.1097/ EDE.0b013e31822939fd
- 37. Navarro C, Chirlaque MD, Tormo MJ, Pérez-Flores D, Rodríguez-Barranco M, et al. Validity of self reported diagnoses of cancer in a major Spanish prospective cohort study. Journal of Epidemiology and Community Health 2006; 60 (7): 593-599. https://doi.org/10.1136/jech.2005.039131
- 38. Cowdery SP, Stuart AL, Pasco JA, Berk M, Campbell D, et al. Validity of self-reported cancer: Comparison between self-report versus cancer registry records in the GEELONG osteoporosis study. Cancer Epidemiology 2020; 68: 101790. https://doi.org/10.1016/j.canep.2020.101790
- 39. Tu H, Wen CP, Tsai SP, Chow WH, Wen C, et al. Cancer risk associated with chronic diseases and disease markers: Prospective cohort study. BMJ 2018; 360: k134. https://doi. org/10.1136/bmj.k134
- 40. Arem H, Loftfield E. Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. American Journal of Lifestyle Medicine 2018; 12 (3): 200-210. https://doi.org/10.1177/1559827617700600
- 41. van de Mortel TF. Faking it: Social desirability response bias in self-report research. Australian Journal of Advanced Nursing 2008; 25 (4): 40-48.
| APA | BAHAR Y, YILDIZ E, Bahar A, Karabudak R (2023). Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. , 962 - 969. 10.55730/1300-0144.5660 |
| Chicago | BAHAR YASEMIN,YILDIZ Egemen,Bahar Abdul Rasheed,Karabudak Rana Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. (2023): 962 - 969. 10.55730/1300-0144.5660 |
| MLA | BAHAR YASEMIN,YILDIZ Egemen,Bahar Abdul Rasheed,Karabudak Rana Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. , 2023, ss.962 - 969. 10.55730/1300-0144.5660 |
| AMA | BAHAR Y,YILDIZ E,Bahar A,Karabudak R Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. . 2023; 962 - 969. 10.55730/1300-0144.5660 |
| Vancouver | BAHAR Y,YILDIZ E,Bahar A,Karabudak R Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. . 2023; 962 - 969. 10.55730/1300-0144.5660 |
| IEEE | BAHAR Y,YILDIZ E,Bahar A,Karabudak R "Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center." , ss.962 - 969, 2023. 10.55730/1300-0144.5660 |
| ISNAD | BAHAR, YASEMIN vd. "Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center". (2023), 962-969. https://doi.org/10.55730/1300-0144.5660 |
| APA | BAHAR Y, YILDIZ E, Bahar A, Karabudak R (2023). Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. Turkish Journal of Medical Sciences, 53(4), 962 - 969. 10.55730/1300-0144.5660 |
| Chicago | BAHAR YASEMIN,YILDIZ Egemen,Bahar Abdul Rasheed,Karabudak Rana Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. Turkish Journal of Medical Sciences 53, no.4 (2023): 962 - 969. 10.55730/1300-0144.5660 |
| MLA | BAHAR YASEMIN,YILDIZ Egemen,Bahar Abdul Rasheed,Karabudak Rana Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. Turkish Journal of Medical Sciences, vol.53, no.4, 2023, ss.962 - 969. 10.55730/1300-0144.5660 |
| AMA | BAHAR Y,YILDIZ E,Bahar A,Karabudak R Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. Turkish Journal of Medical Sciences. 2023; 53(4): 962 - 969. 10.55730/1300-0144.5660 |
| Vancouver | BAHAR Y,YILDIZ E,Bahar A,Karabudak R Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center. Turkish Journal of Medical Sciences. 2023; 53(4): 962 - 969. 10.55730/1300-0144.5660 |
| IEEE | BAHAR Y,YILDIZ E,Bahar A,Karabudak R "Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center." Turkish Journal of Medical Sciences, 53, ss.962 - 969, 2023. 10.55730/1300-0144.5660 |
| ISNAD | BAHAR, YASEMIN vd. "Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center". Turkish Journal of Medical Sciences 53/4 (2023), 962-969. https://doi.org/10.55730/1300-0144.5660 |
